Dosing And Administration

Dosing and administration of Mirataz®

Administer topically by applying a 1.5-inch ribbon of ointment (approximately 2 mg/cat equal to 0.1 mL) on the inner pinna of the cat’s ear once daily for 14 days (see diagram below).

Step 1:
Wear disposable gloves. Twist cap on tube counterclockwise to open.

Step 2:
Apply even pressure on tube and squeeze a 1.5-inch line of ointment onto your gloved finger using the measured line on the carton or in the package insert.

Step 3:
Using your gloved finger, gently rub ribbon of ointment on inside pinna of the cat’s ear spreading it evenly over the surface. Dispose of used gloves after each application. If contact with your skin occurs wash thoroughly with soap and warm water.

After application, care should be taken that people or other animals in the household do not come in contact with the treated cat for 2 hours because mirtazapine can be absorbed transdermally and orally.

Click to learn how to apply Mirataz.

Mirataz is indicated for the management of weight loss in cats.

Important Safety Information

Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients. Do not use in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves when handling/applying, wash hands after and avoid contact between the treated cat and people or other animals for 2 hours following application. Use with caution in cats with hepatic and kidney disease. Cat’s food intake should be monitored upon discontinuation. Safety has not been evaluated in cats less than 2 kg, less than six months of age or in breeding, pregnant or lactating cats. The most common adverse reactions observed during clinical trials were application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. For product label, including complete safety information, click here.

US Patent 10,603,272
Mirataz® is a registered trademark of Dechra Ltd.